No significant differences were noted in target area non-vellus hair count at 24 weeks among women with androgenetic alopecia who received monthly or biweekly microneedling with topical minoxidil vs ...

Whereas both dosing regimens of abrocitinib were effective among patients with atopic dermatitis, continuous treatment with abrocitinib 200 mg was associated with greater efficacy rates than variable ...

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug ...

In a health service area with more than 4 dermatologists per 100,000 population vs areas with no dermatologists, the proportion of late-stage melanoma diagnoses was reduced by 20%. Higher ...

Researchers studied the effectiveness of a food supplement on improving hair density among patients with non-illness-related hair thinning and loss.

Most US adults engage with health-related information on social media, but many also express limited confidence in the accuracy of such information.

Rheumatoid factor may be associated with more significant disease burden and less response to treatment in patients with PsA.

Among patients with psoriasis or atopic dermatitis who had phenotype switching, Janus kinase inhibitors were the most commonly used treatments for therapy modification. Treatment-associated phenotype ...

The FDA approval of marketing for new nicotine pouches has sparked widespread criticism that is backed by recent survey results, which revealed that 1.7% of middle and high school students now use ...

In September 2024, the US Food and Drug Administration (FDA) approved Ebglyss (lebrikizumab-lbkz; Eli Lilly and Company), an interleukin (IL)-13 antagonist, for the treatment of moderate to severe ...